Sepranolone - Asarina Pharma
Alternative Names: Isoallopregnanolone; UC-1010Latest Information Update: 06 Apr 2023
At a glance
- Originator Umecrine Mood
- Developer Asarina Pharma
- Class Antidepressants; Antimigraines
- Mechanism of Action GABA A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gilles de la Tourette's syndrome; Menstrual migraine; Premenstrual dysphoric disorder
Most Recent Events
- 31 Mar 2023 Phase-II clinical trials in Gilles de la Tourette's syndrome (In children, In adults) in Denmark (SC)(NCT05434546)
- 31 Mar 2023 Asarina Pharma completes a phase II trial in Gilles-de-la-Tourette's-syndrome in Denmark (NCT05434546)
- 15 May 2021 Asarina Pharma and Scandinavian CRO complete a phase II trial in Menstrual migraine (In adults) in Finland and Sweden (SC) (NCT04102995) (EudraCT 2019-001081-15)